Depatuxizumab
Depatuxizumab (also known as ABT-806) is a monoclonal antibody designed for the treatment of cancer. It is a humanized antibody that targets the epidermal growth factor receptor (EGFR), which is often overexpressed in various types of cancer cells.
Mechanism of Action[edit | edit source]
Depatuxizumab works by binding to the EGFR on the surface of cancer cells. EGFR is a receptor tyrosine kinase that, when activated, triggers a cascade of downstream signaling pathways that promote cell proliferation, survival, and migration. By binding to EGFR, depatuxizumab inhibits these signaling pathways, thereby reducing tumor growth and inducing apoptosis in cancer cells.
Clinical Development[edit | edit source]
Depatuxizumab has been investigated in several clinical trials for its efficacy and safety in treating different types of cancer, including glioblastoma and non-small cell lung cancer. The drug has shown promise in preclinical studies and early-phase clinical trials, particularly in patients whose tumors express high levels of EGFR.
Side Effects[edit | edit source]
As with many monoclonal antibodies, depatuxizumab can cause a range of side effects. Common side effects include infusion-related reactions, skin rash, and gastrointestinal disturbances. More serious adverse effects may include severe allergic reactions and potential impacts on liver function.
Regulatory Status[edit | edit source]
As of the latest updates, depatuxizumab is still under investigation and has not yet received approval from major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the use of depatuxizumab in combination with other therapeutic agents, such as chemotherapy and radiotherapy, to enhance its efficacy. Additionally, studies are exploring biomarkers that can predict patient response to depatuxizumab, which could lead to more personalized treatment strategies.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Epidermal growth factor receptor
- Cancer immunotherapy
- Glioblastoma
- Non-small cell lung cancer
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
